WARNING: “Buffett Indicator” flashing for first time in 50 years

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

Danny Dearen Biography and Net Worth

Insider of Axonics

Danny L. Dearen founded Axonics, Inc.

He is President & Chief Financial Officer at this company.

He is also on the board of Endotronix, Inc. and Allevion Therapeutics, Inc.

In the past he was Chief Financial Officer & Executive Vice President for SkyDesk, Inc., Chief Financial Officer of ESI Software, Inc., Chief Financial Officer of Fairbanks Systems Group, Chief Financial & Operating Officer at Vessix Vascular, Inc., Chief Financial Officer for Quantitative Three-Dimensional Microscopy, Inc., Chief Financial Officer of Miraval Holding LLC, Chief Financial Officer of Medication Delivery Devices, Inc., Principal at Ventana Growth Fund and Principal at Ernst & Whinney.

He received an undergraduate degree from Southern Methodist University and an MBA from Boston College.

What is Danny L. Dearen's net worth?: The estimated net worth of Danny L. Dearen is at least $1.69 million as of September 29th, 2023. Mr. Dearen owns 23,777 shares of Axonics stock worth more than $1,687,691 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Dearen may own. Learn More about Danny L. Dearen's net worth.
How do I contact Danny L. Dearen?: The corporate mailing address for Mr. Dearen and other Axonics executives is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. Axonics can also be reached via phone at (949) 396-6322 and via email at [email protected]. Learn More on Danny L. Dearen's contact information.
Has Danny L. Dearen been buying or selling shares of Axonics?: Danny L. Dearen has not been actively trading shares of Axonics over the course of the past ninety days. Most recently, Danny L. Dearen sold 7,675 shares of the business's stock in a transaction on Friday, September 29th. The shares were sold at an average price of $56.87, for a transaction totalling $436,477.25. Following the completion of the sale, the chief financial officer now directly owns 23,777 shares of the company's stock, valued at $1,352,197.99. Learn More on Danny L. Dearen's trading history.
Who are Axonics' active insiders?: Axonics' insider roster includes Juliet Bakker (Director), Raymond Cohen (Co-Founder, Chief Executive Officer and Director), Danny Dearen (Insider), Alfred Ford, Jr. (Insider), Kari Keese (CFO), Jane Kiernan (Director), Esteban Lopez (Director), Robert Mcnamara (Director), Karen Noblett (Insider), Rinda Sama (COO), and John Woock (CMO). Learn More on Axonics' active insiders.
Are insiders buying or selling shares of Axonics?: During the last year, insiders at the sold shares 8 times. They sold a total of 92,797 shares worth more than $6,275,226.67. The most recent insider tranaction occured on October, 2nd when CFO Kari Leigh Keese sold 2,961 shares worth more than $205,523.01. Insiders at Axonics own 1.9% of the company. Learn More about insider trades at Axonics.
Information on this page was last updated on 10/2/2024.

Danny L. Dearen Insider Trading History at Axonics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/29/2023	Sell	7,675	$56.87	$436,477.25	23,777
5/26/2023	Sell	7,999	$49.46	$395,630.54	9,202
4/20/2023	Sell	2,001	$60.01	$120,080.01	23,993
3/31/2023	Sell	15,000	$55.27	$829,050.00	23,993
1/31/2023	Sell	10,511	$61.16	$642,852.76	27,239
9/13/2022	Sell	656	$75.60	$49,593.60	7,500
8/11/2022	Sell	50,000	$70.89	$3,544,500.00	8,156
3/1/2022	Sell	19,910	$57.70	$1,148,807.00
2/25/2022	Sell	10,000	$57.00	$570,000.00
2/1/2022	Sell	20,000	$48.70	$974,000.00
1/18/2022	Sell	20,000	$50.93	$1,018,600.00
5/21/2021	Sell	6,866	$55.22	$379,140.52	38,291
4/21/2021	Sell	25,000	$61.63	$1,540,750.00	85,000
7/7/2020	Sell	709	$40.00	$28,360.00	57,200
6/22/2020	Sell	45,000	$38.11	$1,714,950.00	84,240
6/18/2020	Sell	30,000	$39.26	$1,177,800.00	84,240
5/19/2020	Sell	15,000	$40.05	$600,750.00	59,213
5/14/2020	Sell	20,000	$34.19	$683,800.00	71,491
5/11/2020	Sell	30,000	$34.86	$1,045,800.00	71,491
3/2/2020	Sell	4,147	$37.00	$153,439.00	12,682
2/26/2020	Sell	15,853	$37.01	$586,719.53	24,388
2/18/2020	Sell	20,000	$34.25	$685,000.00	36,388
2/13/2020	Sell	103	$34.00	$3,502.00	36,388
1/23/2020	Sell	20,000	$31.46	$629,200.00	28,491
12/19/2019	Sell	30,000	$26.07	$782,100.00	48,491
11/21/2019	Sell	30,000	$21.61	$648,300.00	78,491
11/19/2019	Sell	30,000	$20.74	$622,200.00	108,491

Danny L. Dearen Buying and Selling Activity at Axonics

Axonics Company Overview

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Today's Range

Now: $70.98

$70.37

$71.05

50 Day Range

MA: $70.61

$69.66

$70.98

2 Week Range

Now: $70.98

$55.09

$71.05

Volume

4,233,300 shs

Average Volume

713,457 shs

Market Capitalization

$3.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82